SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-24-000079
Filing Date
2024-02-27
Accepted
2024-02-27 07:04:11
Documents
17
Period of Report
2024-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20240227.htm   iXBRL 8-K 33512
2 EX-99.1 zntl_q42023earningspr.htm EX-99.1 72650
7 zenalis_primarybluenavya.jpg GRAPHIC 68307
  Complete submission text file 0001725160-24-000079.txt   363276

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20240227.xsd EX-101.SCH 2158
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20240227_def.xml EX-101.DEF 5518
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20240227_lab.xml EX-101.LAB 30802
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20240227_pre.xml EX-101.PRE 17930
18 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20240227_htm.xml XML 2821
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 24681923
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)